ALPA LABORATORIES LTD.

Alpa Laboratories Ltd has filed its Annual Report for the financial year ended March 31, 2026, as per SEBI (LODR) Regulations, 2015. The report includes the Notice for the 38th Annual General Meeting (AGM), which will be held on September 30, 2026, via video conference. The company, established in 1988 and based in Indore, has focused on strengthening its pharmaceutical capabilities and product portfolio. The report details corporate information, board and committee structures, financial statements, and management discussion and analysis.

Alpa Laboratories Ltd. has appointed Mrs. Radhika Biyani as an Additional Director in the Independent, Non-Executive category. Her appointment, effective September 5, 2026, follows the completion of Mrs. Jyoti Jain's tenure. The board approved the appointment on August 13, 2026, subject to shareholder approval and DIN allotment, which has since been completed. The company also reconstituted its Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, and Risk Management Committee to ensure compliance with SEBI Listing Regulations. The company has implemented measures to improve director tenure tracking and DIN processes.

Alpa Laboratories Ltd. announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a profit after tax of ₹103.84 lacs for the quarter. Revenue from operations stood at ₹2,393.05 lacs. The Board of Directors also approved the notice for the 38th Annual General Meeting. The results were reviewed by the Audit Committee and approved by the Board, with the Statutory Auditor providing a limited review report.

Alpa Laboratories Ltd has issued a clarification regarding the date of its upcoming Board Meeting. The company states that the correct date for the meeting is Thursday, August 13, 2026, at 3:00 PM, to be held at the registered office. This correction addresses a typographical error where August 14, 2026, was mistakenly mentioned in the subject line of a previous submission. The company confirms that all prior intimations and XBRL filings accurately reflect the August 13th date.

Alpa Laboratories Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda items include the consideration and approval of the standalone and consolidated unaudited financial results for the quarter ending June 30, 2026. Additionally, the board will discuss and approve the notice for the company's 38th Annual General Meeting. Other matters as decided by the board may also be addressed during the meeting.

Alpa Laboratories Ltd has received in-principle approval to explore the promotion and incorporation of an overseas company in Nigeria, tentatively named 'Alpa Biopharm Limited'. This venture, in association with Blueseal Pharmaceuticals Limited, Nigeria, aims to engage in pharmaceutical and healthcare-related business activities. The company has stated that the proposed entity has not yet been incorporated and no investment has been made. Further disclosures will be made upon any material events. This move signifies a potential international expansion strategy for Alpa Laboratories.

Alpa Laboratories Ltd's board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also approved the auditor's report with an unmodified opinion. M/s S. S. Gandhi & Associates and M/s. Sudeep Saxena & Associates were appointed as Internal Auditor and Cost Auditor for the financial year 2026-27, respectively. The meeting, held on May 29, 2026, commenced at 4:00 PM and concluded at 10:00 PM.

Alpa Laboratories Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board will also review the auditor's report issued by M/s C.H Padliya & Co., Chartered Accountants. The meeting will be held at the company's registered office at 4:00 P.M.

Alpa Laboratories Ltd, in response to an email dated 8th April 2026, has clarified that there is no price sensitive information that has not been disclosed. The company does not have any future announcements that may impact the price or volume of the scrip.

Alpa Laboratories Ltd has announced the closure of its trading window, which will remain closed from 01st April 2026 till 48 hours after the declaration of the Financial results for the fourth quarter and financial year ending March 31, 2026. This decision is in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2018, and the company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders.